Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis

Sponsor
Imperial College Healthcare NHS Trust
Study ID
NCT02841176
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 95 Years
Healthy Volunteers
Not accepted

Interventions

  • Thermography — OTHER
    Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
  • Golimumab — BIOLOGICAL
    Participants will start monthly Golimumab after their baseline visit

Study Details

This study will be an open label pilot study to explore the utility of thermography in assessing response to Golimumab treatment in Psoriatic Arthritis (PsA). Ten patients fulfilling the Classification criteria for Psoriatic Arthritis (CASPAR) for Psoriatic Arthritis with active disease and eligible for anti-TNF therapy will be invited to participate in this study. They will be assessed at 4 time points during the study: prior to their first anti-TNF medication (screening and basal visits), and subsequently within 5 days after their 2nd and 4th doses of monthly Golimumab.

Key Dates

Start date
Jul 31, 2016
Status verified
Aug 2017
Primary completion
Sep 19, 2017
Completion
Sep 19, 2017

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Experimental
    Thermography and Golimumab (solution for subcutaneous injection, 50 or 100 mg, monthly)

Primary Outcome Measure

Temperature over arthritic joint surface, measured by thermography [ Time Frame: From baseline up to 97 days ]

Related Studies